Monthly Prescribing Reference

Definity Approved for Use in Pediatric Patients With Suboptimal Echocardiograms

Findings from pediatric trials showed left ventricular opacification with Definity was successful and provided important information to guide patient management. The Food and Drug Administration (FDA) ...
Fierce Healthcare

Lantheus Medical Imaging Announces FDA Accepts for Review DEFINITY® Supplemental New Drug Application for Use in Stress

N. BILLERICA, Mass.--(BUSINESS WIRE)-- Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced that the U.S. Food and Drug Administration (FDA) has accepted ...
Medscape

FDA Backpedals on Warnings in Echo-Contrast Labeling

May 13, 2008 - The US FDA has approved less ominous and restrictive language for the labeling of the echocardiographic contrast agents perflutren lipid microspheres injectable suspension (Definity, ...
Medscape

FDA Puts Boxed Warning on Echo Contrast Agents

October 15, 2007 (Rockville, MD)-As expected, the US FDA has requested that a boxed warning be added to the labeling of two contrast agents used in echocardiography: perflutren liquid microspheres ...
Healio

FDA approves cardiac ultrasound enhancing agent for pediatric patients

Please provide your email address to receive an email when new articles are posted on . The FDA approved perflutren lipid microsphere injection to improve ultrasound imaging in pediatric patients. The ...
Business Wire

Lantheus Medical Imaging Announces FDA Approval of DEFINITY ® Label Update

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Medical Imaging, Inc. (“Lantheus”) today announced U.S. Food and Drug Administration (FDA) approval of an important label update for DEFINITY ® Vial ...